Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Notes Payables: 2013-2021

Historic Notes Payables for Coherus Oncology (CHRS) over the last 1 years, with Sep 2021 value amounting to $81.0 million.

  • Coherus Oncology's Notes Payables was N/A to $81.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $81.0 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2013, which is N/A change from last year.
  • Latest data reveals that Coherus Oncology reported Notes Payables of $81.0 million as of Q3 2021, which was up 0.46% from $80.6 million recorded in Q2 2021.
  • In the past 5 years, Coherus Oncology's Notes Payables registered a high of $81.0 million during Q3 2021, and its lowest value of $80.2 million during Q1 2021.
  • For the 1-year period, Coherus Oncology's Notes Payables averaged around $80.6 million, with its median value being $80.6 million (2021).